Stay updated on Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.

Latest updates to the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated to v3.5.0; revision v3.4.3 was removed.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision: v3.4.3 added and v3.4.2 removed; this is a minor versioning update with no changes to study data or page behavior.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedAdded 'Oropharynx cancer' as a related condition and a new 'Genetic and Rare Diseases Information Center' resource under Resources.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1, and removed the government funding status notice about potential delays.SummaryDifference0.3%

- Check56 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and potential delays, with status links; updated the site version to v3.4.1 (from v3.4.0).SummaryDifference0.3%

- Check63 days agoChange DetectedAdded a Show glossary option and updated several labels and version text, including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while removing the older phrasing 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

Stay in the know with updates to Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.